ADDRESS: Street, City, Country
PHONE: +(123) 456 789
E-MAIL: your-email@mail.com
The EU has cleared Sanofi’s Cenrifki (tolebrutinib) as the first therapy to target disability progression in secondary progressive multiple sclerosis without relapses, while Japan has approved Wayrilz for immune thrombocytopenia (ITP).
imphoenix82
Abu Dhabi DoH and Sanofi have strengthened their partnership to advance vaccine innovation and to jointly explore the development of a Vaccine Innovation Centre in Abu Dhabi.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 8447496924
HealthXploreIndia @2026. All Rights Reserved.
